Abbisko Cayman's (HKG:2256) unit, Abbisko Therapeutics, reported "positive top-line results" for its Phase 3 MANEUVER study of pimicotinib after the study met primary endpoint with a response rate of 54% at week 25 compared with 3.2% for placebo, according to a Tuesday filing with the Hong Kong bourse.

Pimicotinib, a small molecule inhibitor of CSF-1R, has shown positive results in patients with tenosynovial giant cell tumor, the filing said.